Gaucher disease is a chronic, progressive, inherited disorder named for the French physician who first described it. It is caused by a deficiency of a specific enzyme called glucocerebrosidase. This enzyme breaks down and recycles certain lipids (fats). In people with Gaucher disease, these lipids, glucocerebrosides, accumulate within cells and interfere with the normal functioning of various organs (liver, spleen, lungs, bone marrow, and brain). The disease is classified into 3 types. In type 1, there is no brain involvement. It is found in adults, accounts for 95% of all cases, and can sometimes have no symptoms. The type 2 condition is uncommon and severe. Brain damage can be extensive. Children usually die by 2 years of age. Type 3 occurs in children and adolescents. It tends to be chronic and slowly progressive and the central nervous system is affected.
It is estimated that approximately 1 in 40 000 to 60 000 persons in the general population has Gaucher disease, or about 10 000 people worldwide. It is the most common disorder in a group of more than 40 diseases classified as lysosomal storage disorders (LSDs). Grouped together, LSDs affect 1 in every 7700 babies born. The September 19, 2007, issue of JAMA includes an article about genetic screening and treatment for Gaucher disease.
Gaucher disease may occur among every nationality and ethnic group but it is most common among Ashkenazi Jews (individuals of particular Jewish descent from Eastern or Central Europe). In this particular ethnic group, the incidence is 1 in 450 persons.
Symptoms of Gaucher disease can vary form the very mild, or even none, to severe. Bone pain or fracture is often the first symptom. Other symptoms may include
Skeletal abnormalities
Hepatomegaly (enlarged liver)
Splenomegaly (enlarged spleen)
Anemia (reduced number of red blood cells)
Excessive fatigue
Bleeding and easy bruising due to thrombocytopenia (low platelet count)
Mental retardation
Dementia
Pingueculae (yellow spots in the eyes)
Abnormal eye movements
A blood test to measure glucocerebrosidase enzyme activity is currently used to determine whether a person has Gaucher disease or may be a carrier. With a confirmation of the diagnosis, disease management has shifted to disease-specific therapies:
Enzyme replacement therapy (ERT)—The goal of ERT is to provide an appropriate amount of needed enzyme.
Substrate reduction therapy (SRT)—The goal is to minimize the amount of production and accumulation of waste material within cells.
Symptom management—Treatment includes pain reduction therapies, blood transfusions, orthopedic surgery, and possible splenectomy (removal of the spleen).
Psychological care—Professional counseling can help patients better manage the difficulties of their disease and the lifestyle changes that might be required.
National Gaucher Foundationhttp://www.gaucherdisease.org
National Organization for Rare Disorders (NORD)http://www.rarediseases.org
To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's web site at http://www.jama.com. Many are available in English and Spanish.
Sources: National Gaucher Foundation, National Organization for Rare Disorders
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 203/259-8724.
TOPIC: GENETIC DISORDERS
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.